Compare PIII & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | DARE |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 320 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 33.4M |
| IPO Year | N/A | 2014 |
| Metric | PIII | DARE |
|---|---|---|
| Price | $9.86 | $1.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.00 | ★ $10.00 |
| AVG Volume (30 Days) | 25.2K | ★ 129.4K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | $7.67 | $2,115.12 |
| Revenue Next Year | $2.36 | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.52 | $1.23 |
| 52 Week High | $16.89 | $3.78 |
| Indicator | PIII | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 21.13 |
| Support Level | $9.95 | N/A |
| Resistance Level | $12.70 | $1.84 |
| Average True Range (ATR) | 0.85 | 0.13 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 15.48 | 6.93 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.